Lumbrokinaza – co o niej wiemy?

Treść, którą próbujesz wyświetlić, jest dostępna tylko dla członków naszej witryny. Jeśli masz już członkostwo, to zaloguj się. Jeśli nie, to zapraszamy do wykupienia pełnego dostępu.

zalogować Kup dostęp
1. Mihara H, et al. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Japanese Journal of Physiology. 1991;41(3):461–472.2. Ma EL, et al. Effects of Rongshuan No 1 (F-1) on the antithrombotic and antiplatelet aggregation. Journal of Shenyang Pharmaceutical University. 2001;18(5):370-372.3. He ZZ, et al. Separation and purification of earthworm fibrinolytic enzyme and the study of anti-thrombosis activity. Chinese Journal of Biochemical Pharmaceutics. 2001;22(6):284-286.4. Zhang J, et al. Experimental study on the effect of lumbrokinase on fibrinolysis in rats. Chinese Journal of Pathophysiology. 2004;20(5):891-892.5. Jiang DS, et al. Inhibition of platelet aggregation in hamsters by lumbrokinase extracted from Eisenia fetida. Journal of Capital Medical University. 1994;15(4):291-294.7. Yang M, et al. Eisenia fetida lumbrokinase research VI – thrombolytic effect in rabbits and protective effects in experimental stroke model in hamsters. Biotechnology. 1995;5(3):9-11.8. Li WY, et al. Observation of treating twenty-seven cases of ischemic stroke patients with lumbrokinase. New Chinese Medicine. 2003;34(4):63-64.9. Zhang HY. Observation of treating acute ischemic stroke with lumbrokinase. Capital Medicine. 2000;7(3):45-46.10. Zhang DJ, et al. Prevention of ischemic stroke recurrence using lumbrokinase. Capital Medicine. 2003;5(10):47-48.12. Sun MY, et al. Clinical Observations of Lumbrokinase Intervention in 60 Coronary Heart Disease Patients with Aspirin Resistance. Chinese Journal of Gerontology. 2009; 29: 760-761. 13. Liu HS. Clinical observation of treating 60 angina patients with lumbrokinase. Tianjin Pharmacy. 2002;14(2):45-46.14. Yi XF, et al. Efficacy of treating unstable angina seniors with lumbrokinase. Capital Medicine. 2002;9(9):57-58.15. Zhou HS, et al. Clinical observation of treating unstable angina seniors with lumbrokinase capsules. Central Plains Medical Journal. 2001;28(9):2-3.17. Song JS, et al. Clinical analysis of treating 17 cases of deep venous thrombosis with lumbrokinase. Occupation and Health. 2001;17(4):111-115.18. Ye SZ, et al. Observation of treating 51 cases of essential hypertension with lumbrokinase. Clinical Medicine. 2007;27(9):59.19. Gao Y, et al. Efficacy of combining lumbrokinase with nimodipine in the treatment of vascular dementia. Journal of Liaoning University of Traditional Chinese Medicine. 2008;10(11):5-7.20. De Cicco M. The prothrombotic state in cancer: pathogenic mechanisms. Crit Rev Oncol Hematol. 2004 Jun;50(3):187-96.21. Molnar S, et al. Procoagulant factors in patients with cancer. Hematology. 2007 Dec;12(6):555-9.22. Falanga A, et al. Hypercoagulability and tissue factor gene upregulation in hematologic malignancies. Semin Thromb Hemost. 2008 Mar;34(2):204-10.23. Francis JL, et al. Effect of antihemostatic agents on experimental tumor dissemination. Thrombosis and Hemostasis. 2002; 28: 29-38.24. Caine GJ, et al. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia. 2002 Nov-Dec;4(6):465-73.25. Clerk CP, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005 Apr 1;23(10):2130-5.26. Kakkar AK, et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004 May 15;22(10):1944-8.27. DeFeo K, et al. Use of dabigatran etexilate to reduce breast cancer progression. Cancer Biol Ther. 2010 Nov 15;10(10):1001-8.28. Li HY, et al. Antitumor activity of earthworm fibrinolytic enzyme. Chinese Pharmacological Bulletin. 2004;20(8):908-910.29. Chen H, et al. Effect of earthworm fibrinolytic enzyme on the inhibition of invasion and metastasis in hepatocellular carcinoma cell. Jiangsu Medical Journal. 2008;34(4):383-385.30. Chang CX, et al. Anti-metastatic activity of earthworm fibrinolytic enzyme on hepatoma cell in vivo. Traditional Chinese Drug Research & Clinical Pharmacology. 2009;20(6):520-524.33. Song WG, et al. Clinical observation of Boluoke with Lotensin, a new therapy for early stage diabetic nephropathy. Jiangxi Medical Journal. 2010 July; 45(7): 667-668.34. Gu XL, et al. Observation of the effectiveness of treating diabetic peripheral neuropathy by lumbrokinase. Chinese Journal of Primary Medicine and Pharmacy. 2003 July; 10(7): 665.38. Wang CL, et al. Progress in lumbrokinase. Progress in Veterinary Med. 2009;30(11):86-90.39. Tang YJ, et al. Lumbrokinase: A review of domestic research literatures. Capital Medicine. 2011;18(6):39-42.40. Serrapeptase Monograph, Natural Health Products Ingredients Database, Health Canada. 2014 February 7. 6. Zhao J, et al. Eisenia fetida Protease-III-1 Functions in Both Fibrinolysis and Fibrogenesis. J Biomed Biotechnol. 2007;2007(5):97654.11. Cao YJ, et al. Oral fibrinogen-depleting agent lumbrokinase for secondary ischemic stroke prevention: results from a multicenter, randomized, parallel-group and controlled clinical trial. Chin Med J (Engl). 2013 Nov;126(21):4060-5.16. Kasim M, et al. Improved myocardial perfusion in stable angina pectoris by oral lumbrokinase: a pilot study. J Altern Complement Med. 2009 May;15(5):539-44.31. Levi M, et al. Infection and inflammation and the coagulation system. Cardiovasc Res. 2003 Oct 15;60(1):26-39.32. Kitchens CS. Concept of hypercoagulability: a review of its development, clinical application, and recent progress. Semin Thromb Hemost. 1985 Jul;11(3):293-315.35. Liao HE, et al. Cardio Protective Effects of Lumbrokinase and Dilong on Second-Hand Smoke-Induced Apoptotic Signaling in the Heart of a Rat Model. Chin J Physiol. 2015 Jun 30;58(3):188-96.36. Fu YT, et al. Porous gelatin/tricalcium phosphate/genipin composites containing lumbrokinase for bone repair. Bone. 2015 Sep;78:15-22.37. Fu YT, et al. Earthworm (Pheretima aspergillum) extract stimulates osteoblast activity and inhibits osteoclast differentiation. BMC Complement Altern Med. 2014 Nov 11;14:440.41. Weng YQ, et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. Int J Mol Sci. 2017 Mar; 18(3): 523.

Related Articles

Back to top button